Hansa Biopharma Ownership

Stocks . Sweden . 
Stock . Hansa Biopharma AB
HNSA Stock  SEK 32.50  0.04  0.12%   
Hansa Biopharma AB has a total of 52.44 Million outstanding shares. 30% of Hansa Biopharma AB outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Hansa Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Hansa Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Hansa Stock Ownership Analysis

About 41.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 13.1. Hansa Biopharma AB had not issued any dividends in recent years. The entity had 1015:964 split on the 16th of March 2015. Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 60 people. To learn more about Hansa Biopharma AB call Sren MSc at 46 46 16 56 70 or check out https://www.hansabiopharma.com.

Hansa Biopharma Outstanding Bonds

Hansa Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hansa Biopharma AB uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hansa bonds can be classified according to their maturity, which is the date when Hansa Biopharma AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Boeing Co 2196 Corp Bond
US097023DG73		View
HSBC Holdings PLC Corp Bond
US404280DR76		View
MPLX LP 52 Corp Bond
US55336VAL45		View
Morgan Stanley 3591 Corp Bond
US61744YAK47		View

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Hansa Stock Analysis

When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY